Abstract
The tachykinins, substance P, neurokinin A and neurokinin B are small peptides expressed in the extrinsic primary afferent nerve fibers and enteric neurons of the gut. Tachykinins exert a variety of biological actions mediated by three distinct receptors, termed NK1, NK2 and NK3, and at the gastrointestinal level these peptides influence motility, electrolyte and fluid secretion and tissue homeostasis. Several intestinal disorders are associated with changes in the expression of the tachykinin system. Thanks to biological studies and receptor cloning, new selective tachykinins antagonists are now available and have been shown to be active in experimental gut disorders. Some of them are now under clinical trial in inflammatory bowel diseases and the irritable bowel syndrome. The body of preclinical data so far available seems to indicate that tachykinin antagonists might be a new therapeutic tool in the treatment of gut disorders.
Current Pharmaceutical Design
Title: Involvement of Tachykinins in Intestinal Inflammation
Volume: 7 Issue: 1
Author(s): S. Evangelista
Affiliation:
Abstract: The tachykinins, substance P, neurokinin A and neurokinin B are small peptides expressed in the extrinsic primary afferent nerve fibers and enteric neurons of the gut. Tachykinins exert a variety of biological actions mediated by three distinct receptors, termed NK1, NK2 and NK3, and at the gastrointestinal level these peptides influence motility, electrolyte and fluid secretion and tissue homeostasis. Several intestinal disorders are associated with changes in the expression of the tachykinin system. Thanks to biological studies and receptor cloning, new selective tachykinins antagonists are now available and have been shown to be active in experimental gut disorders. Some of them are now under clinical trial in inflammatory bowel diseases and the irritable bowel syndrome. The body of preclinical data so far available seems to indicate that tachykinin antagonists might be a new therapeutic tool in the treatment of gut disorders.
Export Options
About this article
Cite this article as:
S. Evangelista , Involvement of Tachykinins in Intestinal Inflammation, Current Pharmaceutical Design 2001; 7 (1) . https://dx.doi.org/10.2174/1381612013398446
DOI https://dx.doi.org/10.2174/1381612013398446 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy The Structure and Pharmacological Functions of Coumarins and Their Derivatives
Current Medicinal Chemistry Endogenous Glutathione Adducts
Current Drug Metabolism Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery HIV Infection and Myocardial Infarction
Current HIV Research Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Insight into Drug Design and Development of Anti-inflammatory Agents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol
Current Drug Targets - Cardiovascular & Hematological Disorders Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Production of Solid Dosage Forms from Non-Degradable Polymers
Current Pharmaceutical Design Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews The Endocrine Function of Adipose Tissue
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents